Search Results - "Romero Pinel, Lucía"

Refine Results
  1. 1
  2. 2

    Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator by Romero-Pinel, Lucía, Bau, Laura, Matas, Elisabet, León, Isabel, Juvany, Roser, Jódar, Ramon, Martínez-Yélamos, Antonio, Martínez-Yélamos, Sergio

    Published in PloS one (29-04-2022)
    “…The efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS) are well known; however, owing to their high costs, determining…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients by Matas, Elisabet, Bau, Laura, Martínez-Iniesta, María, Romero-Pinel, Lucía, Mañé, M Alba, Cobo-Calvo, Álvaro, Martínez-Yélamos, Sergio

    Published in PloS one (14-11-2014)
    “…Myxovirus resistance protein A (MxA) is a molecule induced after interferon-beta injection, mostly used to evaluate its bioactivity. There is little available…”
    Get full text
    Journal Article
  6. 6

    Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series by Cobo Calvo, Alvaro, Mañé Martínez, M Alba, Alentorn-Palau, Agustí, Bruna Escuer, Jordi, Romero Pinel, Lucía, Martínez-Yélamos, Sergio

    Published in BMC neurology (03-10-2013)
    “…In 2002, the Transverse Myelitis Consortium Working Group (TMCWG) proposed the diagnostic criteria for idiopathic acute transverse myelitis (IATM) to delimit…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades by Romero-Pinel, Lucía, Bau, Laura, Matas, Elisabet, León, Isabel, Muñoz-Vendrell, Albert, Arroyo, Pablo, Masuet-Aumatell, Cristina, Martínez-Yélamos, Antonio, Martínez-Yélamos, Sergio

    Published in Multiple sclerosis and related disorders (01-12-2022)
    “…•Relapsing-remitting multiple sclerosis (RRMS) onset usually occurs between age 20 and 40 years.•This study investigated how age at RRMS onset has changed over…”
    Get full text
    Journal Article
  13. 13

    Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis by Martínez, M Alba Mañé, Olsson, Bob, Bau, Laura, Matas, Elisabet, Calvo, Álvaro Cobo, Andreasson, Ulf, Blennow, Kaj, Romero-Pinel, Lucia, Martínez-Yélamos, Sergio, Zetterberg, Henrik

    Published in Multiple sclerosis (01-04-2015)
    “…Objective: To investigate glial and neuronal biomarkers in cerebrospinal fluid (CSF) samples from patients with relapsing–remitting multiple sclerosis (RRMS)…”
    Get full text
    Journal Article
  14. 14

    Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment by Muñoz-Vendrell, Albert, Arroyo-Pereiro, Pablo, León, Isabel, Bau, Laura, Matas, Elisabet, Martínez-Yélamos, Antonio, Martínez-Yélamos, Sergio, Romero-Pinel, Lucía

    Published in Journal of neurology (01-05-2023)
    “…Background Natalizumab (NTZ) and ocrelizumab (OCR) can be used for the treatment of relapsing–remitting multiple sclerosis (RRMS). In patients treated with…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort by Bau, Laura, Matas, Elisabet, Romero-Pinel, Lucía, León, Isabel, Muñoz-Vendrell, Albert, Arroyo-Pereiro, Pablo, Martínez-Yélamos, Antonio, Martínez-Yélamos, Sergio

    Published in Neurological sciences (17-09-2024)
    “…People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20